Tag Archives: Patent Trial and Appeal Board

Abbvie’s biosimilar fight over Humira patent highlights differences between EU and US regulatory mindsets






The News: Coherus BioSciences Inc. (Redwood City CA) last week announced that the Patent Trial and Appeal Board (PTAB) of the US Patent and Trademark Office ruled in the company’s… Read more »

Week’s opening stock roundup: gainers include Novocure, Steadymed; but Corvus, NewLink rocked






Here to start your trading week are the major movers from last week and where they stand this morning: Novocure (Nasdaq: NVCR) led advancing issues, soaring $3.25, or 40% over the… Read more »

Teva loses four patents on Copaxone; alright, what’s the good news?






The News: A US court invalidated four patents covering Teva Pharmaceutical Industries Ltd.’s (Petach Tikva ISR) three-times weekly version of Copaxone (glatiramer acetate) based on obviousness, following a challenge by… Read more »

Good News for Mylan after Hellish Week: Another Win in Patent War Over MS Drug; Lawyers on Both Sides Rejoice.






Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) had a third patent on its top-selling multiple sclerosis drug, Copaxone, invalidated last Thursday by a U.S. agency, a further blow to its… Read more »